Longeveron experienced a decrease in revenue and an increased net loss in Q2 2025 compared to the previous year, primarily due to reduced demand for its clinical trial and contract manufacturing services. Despite financial setbacks, the company achieved full enrollment for its pivotal Phase 2b clinical trial (ELPIS II) for HLHS and received FDA approval for its IND application for Pediatric Dilated Cardiomyopathy, signaling significant progress in its development pipeline.

Longeveron Inc. experienced a challenging first quarter in 2025, with total revenues decreasing to $381,000 from $548,000 in the prior year. The company's net loss widened to $5,011,000, compared to $4,058,000 in Q1 2024, driven by increased operating expenses, particularly in general and administrative costs and research and development. The decrease in revenue was primarily attributed to lower participant demand for the Bahamas Registry Trial, despite an increase in contract manufacturing revenue.

Longeveron Inc. reported a significant increase in total revenue for the first nine months of 2024, up 177% year-over-year to $1.8 million, primarily driven by contract manufacturing services and increased participant demand for the Bahamas Registry Trial. The company also reduced total operating expenses by 14% year-over-year while advancing its clinical pipeline, and expects current cash and cash equivalents to fund operations through Q4 2025.

Longeveron Inc. reported financial results for the quarter ended September 30, 2024, and provided a business update, highlighting the advancement of Lomecel-BTM for HLHS and mild Alzheimer’s disease.

Longeveron Inc. reported on the progress of its investigational cellular therapy candidate, Lomecel-B™, for Alzheimer’s disease and Hypoplastic Left Heart Syndrome (HLHS). The U.S. FDA granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease. The company believes it has sufficient capital to fund operations through the fourth quarter of 2025.

Longeveron reported revenue of $0.3 million and a net loss of $4.6 million for the first quarter of 2023. The company's cash and marketable securities totaled $13.7 million as of March 31, 2023.

Longeveron reported fourth quarter revenue of $0.1 million and a net loss of $4.5 million. The company's cash and short-term investments totaled $19.6 million. They believe that existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.

Longeveron Inc. reported revenue of $0.3 million and a net loss of $5.2 million for the third quarter ended September 30, 2022. The company's cash and short-term investments were $22.3 million as of September 30, 2022.

Longeveron reported revenue of $0.5 million for the second quarter of 2022, the same as in 2021. Net loss was $5.6 million, compared to $5.0 million for the same period in 2021. Cash and short-term investments totaled $27.0 million as of June 30, 2022.

Longeveron announced its financial results for the quarter ended March 31, 2022, but the specific details were not provided in the text.

Longeveron reported fourth quarter revenue of $0.2 million and a net loss of $4.1 million. The company's cash and short-term investments were $35.0 million. They believe that their existing cash and short-term investments will be sufficient to cover expenses and capital requirements into 2024.

Longeveron Inc. reported revenue of $0.2 million and a net loss of $4.9 million for the third quarter of 2021. The company's cash and short term investments amounted to $19.0 million. They believe that their existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

Longeveron Inc. reported revenue of $0.5 million and a net loss of $5.0 million for the second quarter of 2021. The company's cash on hand was $16.8 million, expected to be sufficient to cover expenses through at least the fourth quarter of 2022.

Longeveron Inc. reported its financial results for the first quarter ended March 31, 2021. The company's revenue was $0.4 million, and net loss was $3.1 million. Cash on hand was $24.5 million, which the company believes will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.